Institution
Mater Misericordiae University Hospital
Healthcare•Dublin, Ireland•
About: Mater Misericordiae University Hospital is a healthcare organization based out in Dublin, Ireland. It is known for research contribution in the topics: Population & Medicine. The organization has 2277 authors who have published 2787 publications receiving 58083 citations. The organization is also known as: The Mater & Ospidéal an Mater Misercordiae.
Topics: Population, Medicine, Breast cancer, Cancer, Health care
Papers published on a yearly basis
Papers
More filters
••
University College London1, Imperial College London2, University of London3, Erasmus University Rotterdam4, French Institute of Health and Medical Research5, Albert Einstein College of Medicine6, Norwegian University of Science and Technology7, University of Washington8, University of Barcelona9, New York State Department of Health10, Monash University11, University of Toronto12, Mayo Clinic13, Mater Misericordiae University Hospital14, UCL Institute of Neurology15, University of Tübingen16
TL;DR: Mutations in LRRK2 are a clinically relevant cause of PD that merit testing in patients with hereditary PD and in subgroups of patients with PD, but this knowledge should be applied with caution in the diagnosis and counselling of patients.
Abstract: Summary Background Mutations in LRRK2 , the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson's disease (PD). The International LRRK2 Consortium was established to answer three key clinical questions: can LRRK2 -associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2 ? Methods Researchers from 21 centres across the world collaborated on this study. The frequency of the common LRRK2 Gly2019Ser mutation was estimated on the basis of data from 24 populations worldwide, and the penetrance of the mutation was defined in 1045 people with mutations in LRRK2 from 133 families. The LRRK2 phenotype was defined on the basis of 59 motor and non-motor symptoms in 356 patients with LRRK2 -associated PD and compared with the symptoms of 543 patients with pathologically proven idiopathic PD. Findings Six mutations met the consortium's criteria for being proven pathogenic. The frequency of the common LRRK2 Gly2019Ser mutation was 1% of patients with sporadic PD and 4% of patients with hereditary PD; the frequency was highest in the middle east and higher in southern Europe than in northern Europe. The risk of PD for a person who inherits the LRRK2 Gly2019Ser mutation was 28% at age 59 years, 51% at 69 years, and 74% at 79 years. The motor symptoms (eg, disease severity, rate of progression, occurrence of falls, and dyskinesia) and non-motor symptoms (eg, cognition and olfaction) of LRRK2 -associated PD were more benign than those of idiopathic PD. Interpretation Mutations in LRRK2 are a clinically relevant cause of PD that merit testing in patients with hereditary PD and in subgroups of patients with PD. However, this knowledge should be applied with caution in the diagnosis and counselling of patients. Funding UK Medical Research Council; UK Parkinson's Disease Society; UK Brain Research Trust; Internationaal Parkinson Fonds; Volkswagen Foundation; National Institutes of Health: National Institute of Neurological Disorders and Stroke and National Institute of Aging; Udall Parkinson's Disease Centre of Excellence; Pacific Alzheimer Research Foundation Centre; Italian Telethon Foundation; Fondazione Grigioni per il Morbo di Parkinson; Michael J Fox Foundation for Parkinson's Research; Safra Global Genetics Consortium; US Department of Veterans Affairs; French Agence Nationale de la Recherche.
1,310 citations
••
Queen Mary University of London1, University of Groningen2, Utrecht University3, University of Debrecen4, National Institutes of Health5, University of Milan6, University Medical Center Utrecht7, Hungarian Academy of Sciences8, Casa Sollievo della Sofferenza9, King's College London10, Wellcome Trust Sanger Institute11, University of Tampere12, Trinity College, Dublin13, Mater Misericordiae University Hospital14, Sapienza University of Rome15, Leiden University16, Mayo Clinic17, University of California, Los Angeles18, University of Helsinki19, University of Naples Federico II20, Beckman Research Institute21, University of Milano-Bicocca22
TL;DR: This article performed a second-generation genome-wide association study of 4,533 individuals with celiac disease (cases) and 10,750 control subjects, and genotyped 113 selected SNPs with P(GWAS) < 10(-4) and 18 SNPs from 14 known loci in a further 4,918 cases and 5,684 controls.
Abstract: We performed a second-generation genome-wide association study of 4,533 individuals with celiac disease (cases) and 10,750 control subjects. We genotyped 113 selected SNPs with P(GWAS) < 10(-4) and 18 SNPs from 14 known loci in a further 4,918 cases and 5,684 controls. Variants from 13 new regions reached genome-wide significance (P(combined) < 5 x 10(-8)); most contain genes with immune functions (BACH2, CCR4, CD80, CIITA-SOCS1-CLEC16A, ICOSLG and ZMIZ1), with ETS1, RUNX3, THEMIS and TNFRSF14 having key roles in thymic T-cell selection. There was evidence to suggest associations for a further 13 regions. In an expression quantitative trait meta-analysis of 1,469 whole blood samples, 20 of 38 (52.6%) tested loci had celiac risk variants correlated (P < 0.0028, FDR 5%) with cis gene expression.
894 citations
••
University of Sydney1, Guy's and St Thomas' NHS Foundation Trust2, University of British Columbia3, Harvard University4, Monash University5, Royal Prince Alfred Hospital6, Garvan Institute of Medical Research7, St. Vincent's Health System8, Auckland City Hospital9, Sydney Adventist Hospital10, Mater Misericordiae University Hospital11, University College Dublin12, University of Alberta13, University of Adelaide14, Queen's University15, Ottawa Hospital Research Institute16, University of Ottawa17, University of Melbourne18, Royal Adelaide Hospital19, Royal Cornwall Hospital20
TL;DR: Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression.
Abstract: Background Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with metastatic, hormone-sensitive prostate cancer. Methods In this open-label, randomized, phase 3 trial, we assigned patients to receive testosterone suppression plus either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy (standard-care group). The primary end point was overall survival. Secondary end points included progression-free survival as determined by the prostate-specific antigen (PSA) level, clinical progression-free survival, and adverse events. Results A total of 1125 men underwent randomization; the median follow-up was 34 months. There were 102 deaths in the enzalutamide group and 143 deaths in the standard-care group (hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.86; P = 0.002). Kaplan-Meier estimates of overall survival at 3 years were 80% (based on 94 events) in the enzalutamide group and 72% (based on 130 events) in the standard-care group. Better results with enzalutamide were also seen in PSA progression-free survival (174 and 333 events, respectively; hazard ratio, 0.39; P Conclusions Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression. The enzalutamide group had a higher incidence of seizures and other toxic effects, especially among those treated with early docetaxel. (Funded by Astellas Scientific and Medical Affairs and others; ENZAMET (ANZUP 1304) ANZCTR number, ACTRN12614000110684; ClinicalTrials.gov number, NCT02446405; and EU Clinical Trials Register number, 2014-003190-42.).
865 citations
Queen Mary University of London1, University of Groningen2, Utrecht University3, University of Debrecen4, National Institutes of Health5, University of Milan6, University Medical Center Utrecht7, Hungarian Academy of Sciences8, Casa Sollievo della Sofferenza9, King's College London10, Wellcome Trust Sanger Institute11, University of Tampere12, Trinity College, Dublin13, Mater Misericordiae University Hospital14, Sapienza University of Rome15, Leiden University16, Mayo Clinic17, University of California, Los Angeles18, University of Helsinki19, University of Naples Federico II20, Beckman Research Institute21, University of Milano-Bicocca22
TL;DR: Variants from 13 new regions reached genome-wide significance and most contain genes with immune functions, with ETS1, RUNX3, THEMIS and TNFRSF14 having key roles in thymic T-cell selection.
Abstract: We performed a second-generation genome-wide association study of 4,533 individuals with celiac disease (cases) and 10,750 control subjects. We genotyped 113 selected SNPs with P(GWAS) < 10(-4) and 18 SNPs from 14 known loci in a further 4,918 cases and 5,684 controls. Variants from 13 new regions reached genome-wide significance (P(combined) < 5 x 10(-8)); most contain genes with immune functions (BACH2, CCR4, CD80, CIITA-SOCS1-CLEC16A, ICOSLG and ZMIZ1), with ETS1, RUNX3, THEMIS and TNFRSF14 having key roles in thymic T-cell selection. There was evidence to suggest associations for a further 13 regions. In an expression quantitative trait meta-analysis of 1,469 whole blood samples, 20 of 38 (52.6%) tested loci had celiac risk variants correlated (P < 0.0028, FDR 5%) with cis gene expression.
845 citations
••
TL;DR: A retrospective analysis suggests that paravertebral anesthesia and analgesia for breast cancer surgery reduces the risk of recurrence or metastasis during the initial years of follow-up.
Abstract: Background: Regional anesthesia is known to prevent or attenuate the surgical stress response; thus, inhibiting surgical stress by paravertebral anesthesia might attenuate perioperative factors that enhance tumor growth and spread. We hypothesized that breast cancer patients undergoing surgery with paravertebral anesthesia and analgesia combined with general anesthesia have a lower incidence of cancer recurrence or metastases than patients undergoing surgery with general anesthesia and patient-controlled morphine analgesia.
Methods: In this retrospective study, we examined the medical records of 129 consecutive patients undergoing mastectomy and axillary clearance for breast cancer between September 2001 and December 2002.
Results: 50 patients had surgery with paravertebral anesthesia and analgesia combined with general anesthesia and 79 patients had general anesthesia combined with postoperative morphine analgesia. The follow-up time was 32±5 months (mean±SD). There were no significant differences in patients or surgical details, tumor presentation, or prognostic factors. Recurrence and metastasis-free survival was 94% (95% CI 87,100) and 82% (74, 91) at 24 months and 94 (87, 100) and 77 (68, 87) at 36 months in the paravertebral and general anesthesia patients, respectively, P=0.012.
Conclusions: This retrospective analysis suggests that paravertebral anesthesia and analgesia for breast cancer surgery reduces the risk of recurrence or metastasis during the initial years of follow-up. Prospective trials evaluating the effects of regional analgesia and morphine sparing on cancer recurrence seem warranted.
844 citations
Authors
Showing all 2294 results
Name | H-index | Papers | Citations |
---|---|---|---|
Marc Humbert | 149 | 1184 | 100577 |
Gérald Simonneau | 130 | 587 | 90006 |
John F. Keaney | 99 | 273 | 38237 |
Declan G. Murphy | 95 | 820 | 37076 |
John V. Reynolds | 92 | 797 | 41654 |
Hugh Garavan | 84 | 419 | 28773 |
Ian H. Robertson | 81 | 362 | 23146 |
William G. Powderly | 77 | 313 | 24857 |
Desmond J. Fitzgerald | 75 | 311 | 19834 |
Michael J. Kerin | 71 | 454 | 21243 |
Cormac T. Taylor | 61 | 163 | 15751 |
Desmond N. Carney | 57 | 182 | 14854 |
Ignacio Martin-Loeches | 56 | 374 | 11549 |
Catherine Godson | 56 | 155 | 10941 |
Daniel Murphy | 56 | 174 | 10793 |